Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

Angela L. Bosma*, Linde E.M. de Wijs, Michel H. Hof, Beau R. van Nieuwenhuizen, Louise A.A. Gerbens, Maritza A. Middelkamp-Hup, Dirk Jan Hijnen, Phyllis I. Spuls

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)e173-e174
JournalJournal of the American Academy of Dermatology
Issue number3
Publication statusPublished - 1 Sept 2021

Bibliographical note

Funding Information:
Funding sources: The original study was partly funded by a governmental grant through ZonMw (The Netherlands Organization for Health Research and Development), program Rational Pharmacotherapy.

Cite this